The identification of the three annotated lncRNAs LINC02418, Lnc-OR1D5-1 and Lnc-PXDN-3 discriminating the ERG-positive subtype of prostate cancer vs. others and the analysis of the co-expressed protein-coding genes and these lncRNAs revealed novel promising pharmacological targets in specific subtypes of prostate cancer. Here, OR1D5 is linked to prostate carcinoma.